Serum Osteoprotegerin Association With Coronary Artery Disease And Type 2 Diabetes Mellitus In Syrian Cohort

Abstract

Abstract:

Background and Aim: Osteoprotegerin (OPG) has emerged as a potential biomarker for cardiovascular diseases (CVD) and type 2 diabetes (T2D). This study aimed to evaluate the relationship between serum OPG levels, fasting blood glucose (FBG), and the presence of coronary artery disease (CAD) in patients with and without T2D.

Materials and methods: A total of 60 participants were enrolled in this cross-sectional study, divided into two groups based on cardiac catheterization results: Non-CAD group (16 patients) with no stenosis in epicardial arteries and CAD group (44 patients) with severe multivessel disease (>50% stenosis in one or more major epicardial arteries). Demographic data, clinical characteristics, and biochemical parameters including FBG and serum OPG levels were measured. Statistical analyses were performed to compare the two groups and assess correlations.

Results: Patients with CAD exhibited significantly higher FBG levels (110.39±42.05 mg/dL) compared to those without CAD (84.75±9.55 mg/dl, P=0.021). Serum OPG levels were also elevated in the CAD group (5.72±2.06 ng/mL) versus the non-CAD group (4.49±1.05 ng/ml, P<0.008). A positive correlation was observed between OPG levels and diabetes status, with higher OPG levels noted in T2D patients (5.91±2.38 ng/ml) compared to non-diabetic individuals (4.91±1.2 ng/ml). ROC curve analysis demonstrated that OPG had an area under the curve (AUC) of 0.726 for predicting CAD risk (P=0.008) and an AUC of 0.661 for predicting T2D risk (P=0.033).

Conclusions: Our findings suggest that elevated serum OPG levels are associated with CAD and T2D, indicating its potential role as a biomarker for cardiovascular risk assessment. Further studies are warranted to explore the mechanistic pathways linking OPG with metabolic and cardiovascular diseases.

Keywords: Coronary Atherosclerosis Disease, Atherosclerosis, Biomarker, Osteoprotegerin, Cardiovascular Risk Factors, Fast Plasma Glucose, Diabetes.